Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Oxygenta Pharmaceutical EBITDA Margin % Related Terms
Oxygenta Pharmaceutical EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Oxygenta Pharmaceutical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxygenta Pharmaceutical EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Oxygenta Pharmaceutical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Oxygenta Pharmaceutical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxygenta Pharmaceutical (BOM:524636) has a EBITDA Margin % of 1.54% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxygenta Pharmaceutical and its competitors. According to the industry distribution chart, Oxygenta Pharmaceutical ranks #762 out of 961 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is Oxygenta Pharmaceutical's EBITDA Margin % too high?
Oxygenta Pharmaceutical's current EBITDA Margin % is 1.54%. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Oxygenta Pharmaceutical's value of 1.54% is 87.6% below this industry median. Based on the distribution chart, Oxygenta Pharmaceutical ranks #762 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Oxygenta Pharmaceutical has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oxygenta Pharmaceutical's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Oxygenta Pharmaceutical ranks #762 out of 961 companies for EBITDA Margin %. This places Oxygenta Pharmaceutical in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Oxygenta Pharmaceutical's value of 1.54% is 87.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxygenta Pharmaceutical's current EBITDA Margin % of 1.54% is 87.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxygenta Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxygenta Pharmaceutical's current EBITDA Margin % is 1.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxygenta Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Oxygenta Pharmaceutical (BOM:524636) is currently considered Possible Value Trap. The stock's GF Value™ is ₹84.23, compared to a current price of ₹51.25 — trading 39.2% below its estimated fair value. The current EBITDA Margin % is 1.54% and 87.6% below the Drug Manufacturers industry median of 12.44. Oxygenta Pharmaceutical's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oxygenta Pharmaceutical (BOM:524636), the current EBITDA Margin % is 1.54% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxygenta Pharmaceutical (BOM:524636) Overvalued in 2026?
Based on GuruFocus' analysis, Oxygenta Pharmaceutical stock appears to be undervalued.
The current stock price of ₹51.25 is trading 39.2% below its estimated GF Value™ of ₹84.23.
GuruFocus considers Oxygenta Pharmaceutical to be Possible Value Trap.
Key valuation signals for BOM:524636:
EBITDA Margin %: 1.54%
GF Value™: ₹84.23 vs. price of ₹51.25 (39.2% below fair value)
Industry Position: 87.6% below the Drug Manufacturers median (#762 of 961)
No single metric tells the full story. See the BOM:524636 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxygenta Pharmaceutical Ltd is a pharmaceutical company. It is engaged in the business activity of is engaged in manufacturing and selling of Pharmaceutical, medical, and veterinary preparations. The Company has one reportable segment, which is Pharmaceutical. The group carries out its business operations within India.
42GF Score
Get the complete analysis for BOM:524636
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524636 has been successfully added to your 
